How Do I Choose Acute Treatment Medication Options for Migraine Patients?
Laura Xanders, FNP-BC Maureen Moriarty, DNP, APRN, FAHS, FAANP Step 1: Conduct a history of present illness (HPI)
What is their migraine frequency? • What is the frequency of the pa ent’s moderate to severe migraine a acks? • What associated symptoms do they experience with their migraine a acks? • Are their migraine a acks rapid or gradual in onset? What do they currently take? • Do they get complete relief? • How o en do they take it? • Can they tolerate oral medica on during a migraine a ack?
What have they tried in the past that has or has not worked? Step 2: Determine any comorbid condi ons or concurrent medica ons that may be a contraindica on to an acute migraine medica on.
A patient with a history of stomach A patient with a history of Pregnancy/lactation status ulcer may not be a good candidate cardiovascular disease or could impact safe or approved for an oral NSAID uncontrolled hypertension use of a medication may not be a good candidate for a triptan Step 3: Review the available acute medica on op ons. 1. NSAIDs • Faster onset: diclofenac powder, ketorolac IM, ketorolac NS • Slower onset: naproxen, ibuprofen, diclofenac, indomethacin 2. Triptans • Short half life: sumatriptan, rizatriptan, eletriptan, almotriptan, zolmitriptan • Long half life: naratriptan, frovatriptan • Non-PO: sumatriptan NS, zolmitriptan NS, sumatriptan SQ 3. Acute CGRP antagonists (gepants) • ubrogepant • rimegepant 4. Ditans • lasmiditan 5. An -eme cs* • metoclopramide • prochlorperazine • promethazine • ondansetron
* Metoclopramide, prochlorperazine and promethazine have addi onal direct an -migraine effect but may be seda ng, and ondansetron has no direct an -migraine effect but is not seda ng. Step 4: Make a treatment ac on plan
If the patient always experiences severe attacks, and fewer than 8 days/month, they may do best with a migraine- specific agent at onset of all attacks.
If frequency is more than 8 days/month, or there is a mix of moderate and severe attacks, use a stratified care and combination approach.
When there is significant nausea use non-oral treatment or add an anti-emetic. Step 5: Clarify medica on limits
Medica on limits exist for safety and to prevent acute medica on overuse.
SUGGESTED LIMITS • If a pa ent is using only simple analgesics, usage up to 15 days/month is considered reasonable. If a pa ent uses other agents in addi on, the limit should be 10 days/month. This recommenda on is to reduce the chances of medica on toxicity and rebound headache. Note: Some common side effects or cau ons
• Triptans - jaw/throat/chest ghtness, palpita ons, ngling, nausea, temporary increase in blood pressure, seda on • Gepants - medica on interac ons (see med insert) • Ditans - seda on, dizziness • NSAIDs - stomach upset • metoclopromide/phenothiazines - tardive dyskinesia, akathisia, seda on, anxiety Acute Medica ons for Migraine Medica on Class Frequency of Treatment/Limits Most Common Side effects Considera ons Triptans All triptans can be repeated once in 2 hours with -Dizziness Can contribute to increased headache Sumatriptan PO, NS, SQ the following excep ons: -Drowsiness frequency if overused Eletriptan PO -Heaviness Frovatriptan PO • Sumatriptan SQ can be repeated in 1 hour Naratriptan PO • Naratriptan can be repeated in 4 hours -Neck/jaw ghtness Contraindicated in pa ents with or at Rizatriptan PO, ODT -Elevated Blood Pressure risk for vascular disease Zolmitriptan PO, NS, ODT Almotriptan PO NSAIDs Every 6-12 hours -Abdominal pain Contraindicated in history of Aspirin PO -Cons pa on gastrointes nal bleed, decreased Ibuprofen PO -Diarrhea kidney func on and/or abnormal liver Naproxen PO Limit to 12-15 days or less per month Diclofenac PO -Nausea/Vomi ng func on with overuse Indomethacin PO *limit to 4 days per month -Heartburn Nabumetone PO *Ketorolac IM, NS Celecoxib PO Gepants U- 1 dose followed by 2nd as needed in 2 hours -Drowsiness (U) Limited long-term data Ubrogepant PO R- limit to 1 dose in 24 hrs -Nausea (U, R) Should not be used in pa ents with Rimegepant ODT -Dry mouth (U) ac ve vascular disease
Ditans Limit to 1 dose in 24hrs -Seda on Limited long-term data Lasmi dan PO -Dizziness Controlled substance -Numbness/Tingling 8 hour driving restric on Should not be used in pa ents with ac ve vascular disease Neurolep cs Up to 3 mes a day -Drowsiness Metoclopramide safe in pregnancy Metoclopramide PO Limit to 10 days per month -Tardive dyskinesi Prochlorperazine PO, PR Promethazine PO, PR
REFERENCES Becker, W. Acute Migraine Treatment in Adults. Headache. 2015;55;778-793 Mallick-Searle T, Moriarty M. Unmet needs in the acute treatment of migraine a acks and the emerging role of calcitonin gene–related pep de receptor antagonists: An integra ve review. J Am Assoc Nurse Pract. 2020;ePub. doi: 10.1097/JXX.0000000000000397 Mayans, L., Walling, A. Acute migraine headache: treatment strategies. Am Fam Physician. 2018 Feb 15;97(4):243-251. Munksgaard, S. & Jensen, R. Medica on Overuse Headache. Headache Currents. 2014. 1251-1257. Moreno-Ajona et al. Targe ng CGRP and 5-HT1F Receptors for the Acute Therapy of Migraine: A Literature Review